This article covers TileBio, a Glasgow healthtech startup, which has closed a seed funding round of £2.3m led by Twin Path Ventures with follow-on investment from Maven Capital Partners, Scottish Enterprise, the University of Glasgow and the Smart Things Accelerator Centre (STAC). The funding is intended to validate its tissue-language foundation model for preclinical toxicology and exploratory biomarker discovery, to de-risk drug development and support a planned Series A.
TileBio, a Glasgow healthtech startup, has closed a seed funding round of £2.261 million led by Twin Path Ventures, with follow-on investment from Maven Capital Partners, Scottish Enterprise, the University of Glasgow and the Smart Things Accelerator Centre (STAC). The money will be used to validate its tissue-language foundation model with applications in preclinical toxicology and exploratory biomarker discovery, a step the company says will de-risk drug development and underpin a planned Series A.
Drug development is costly and failure-prone, particularly when preclinical readouts do not translate to clinical outcomes. TileBio’s approach aims to extract consistent, reproducible signals from whole-slide histology images using a foundation model trained on unlabelled data, which could standardise how treatment-related tissue changes are detected across studies. If successful, that would reduce uncertainty for pharma partners and make preclinical pipelines more efficient.
The round also signals continued investor interest in AI-enabled pathology tools, and it strengthens links between industry, academia and the NHS in Scotland.
TileBio describes its core technology as a tissue-language foundation model that learns directly from unlabelled whole-slide images. The company is initially applying the model in two product tracks.
TileBio Precedent focuses on preclinical toxicology, aiming to flag and quantify treatment-related morphology consistently across studies so that toxic signals can be compared more reliably between experiments.
TileBio Motif targets exploratory biomarker discovery, seeking tissue phenotypes associated with outcome and treatment response in partner cohorts.
The company says validation in these two areas will form the basis of its Series A and support a longer-term roadmap toward clinical diagnostics.
The round was led by Twin Path Ventures. Follow-on investors named in the announcement are Maven Capital Partners, Scottish Enterprise, the University of Glasgow and the Smart Things Accelerator Centre (STAC). Scottish Enterprise is the national economic development agency for Scotland and the University of Glasgow is participating as both a research partner and investor. STAC is listed as a regional accelerator collaborator.
This mix of private venture capital, public economic support and academic backing underlines the company’s positioning at the intersection of research translation and commercialisation. Investors’ stated focus in the announcement is on supporting validation work that could reduce downstream clinical risk and prepare TileBio for a Series A.
If you're researching potential backers in this space:
TileBio framed the raise as funding for validation activities rather than immediate commercial roll-out. The company said the seed capital will support work that demonstrates the model’s ability to detect and quantify treatment-related histology changes and to identify biomarker candidates in partner cohorts. The announcement also references a previous disclosure of £1.6 million in seed funding in February 2026, positioning this latest close as a continuation of the company’s early-stage funding trajectory.
The deal contributes to growing activity around AI pathology and image-based biomarker discovery in the UK, where university spinouts, regional accelerators and NHS collaborations are common routes to test new diagnostics and preclinical tools. TileBio’s partnerships with NHS Greater Glasgow & Clyde and the NHS West of Scotland Innovation Hub reflect that public-private testing pathway.
If TileBio can demonstrate reproducible preclinical readouts, it may find a market among pharmaceutical companies seeking to reduce late-stage failures. The outcome of its validation work will be a useful bellwether for investors and other healthtech startups working on image-first AI models across Europe.
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
![]() Twin Path Ventures( ) Twin Path Ventures is a venture capital firm focused on investing in AI-first st... London | ||||
![]() Maven Capital Partners( ) Maven is a leading UK private equity firm specialising in buyouts, growth capita... London | ||||
![]() Scottish Enterprise( ) The firm focuses on supporting early-stage and growing companies in Scotland, of... Glasgow | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK